<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Res</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Res</journal-id><journal-id journal-id-type="pmc-domain-id">2082</journal-id><journal-id journal-id-type="pmc-domain">jdrsch</journal-id><journal-id journal-id-type="publisher-id">JDR</journal-id><journal-title-group><journal-title>Journal of Diabetes Research</journal-title></journal-title-group><issn pub-type="ppub">2314-6745</issn><issn pub-type="epub">2314-6753</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11309811</article-id><article-id pub-id-type="pmcid-ver">PMC11309811.1</article-id><article-id pub-id-type="pmcaid">11309811</article-id><article-id pub-id-type="pmcaiid">11309811</article-id><article-id pub-id-type="pmid">39118831</article-id><article-id pub-id-type="doi">10.1155/2024/9958586</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Relationship Between Glycosylated Hemoglobin Variability and the Severity of Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="X">Xinyan</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-3875-6528</contrib-id><name name-style="western"><surname>Yang</surname><given-names initials="X">Xiyao</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1156-3231</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="N">Na</given-names></name><email>3441535223@qq.com</email><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>
<institution content-type="dept">Department of Endocrinology</institution>
<institution content-type="edu">Shengjing Hospital of China Medical University</institution>, Shenyang 110004, China</aff><aff id="I2">
<sup>2</sup>
<institution content-type="dept">Department of Endocrinology</institution>
<institution content-type="edu">The First Hospital of China Medical University</institution>, Shenyang 110004, China</aff><aff id="I3">
<sup>3</sup>
<institution content-type="dept">Department of Pediatrics</institution>
<institution content-type="edu">Shengjing Hospital of China Medical University</institution>, Shenyang 110004, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Ramatchandirin Balamurugan</p></fn></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>1</day><month>8</month><year>2024</year></pub-date><volume>2024</volume><issue-id pub-id-type="pmc-issue-id">453221</issue-id><elocation-id>9958586</elocation-id><history><date date-type="received"><day>2</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>5</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>08</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 17:25:27.790"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Xinyan Liu et al.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JDR2024-9958586.pdf"/><abstract><p>
<bold>Background:</bold> Glycosylated hemoglobin (HbA1c) variability is a risk factor for cardiovascular complications in patients with Type 2 diabetes mellitus (T2DM), but its relationship with the severity of coronary artery disease (CAD) is unclear.</p><p>
<bold>Methods:</bold> Patients with T2DM who underwent coronary angiography due to angina were enrolled. HbA1c variability was expressed as coefficient of variation (CV), standard deviation (SD), variability independent of mean (VIM), and time in range (TIR). The severity of CAD was expressed by the number of involved vessels and Gensini score. Multivariate regression models were constructed to test the relationship between HbA1c variability, number of involved vessels, and the Gensini score, followed by linear regression analysis.</p><p>
<bold>Results</bold>: A total of 147 patients were included. In multivariate analysis, VIM-HbA1c (OR = 2.604; IQR: 1.15, 5.90; <italic toggle="yes">r</italic> = 0.026) and HbA1cTIR (OR = 0.13; IQR: 0.04, 0.41; <italic toggle="yes">r</italic> &lt; 0.001) were independent risk factors for the number of involved vessels. After adjustment, HbA1cTIR (OR = 0.01; IQR: 0.002, 0.04; <italic toggle="yes">r</italic> &lt; 0.001), SD-HbA1c (OR = 4.12, IQR: 1.64, 10.35; <italic toggle="yes">r</italic> = 0.001), CV-HbA1c (OR = 1.41, IQR: 1.04, 1.92; <italic toggle="yes">r</italic> = 0.007), and VIM-HbA1c (OR = 3.26; IQR: 1.43, 7.47; <italic toggle="yes">r</italic> = 0.003) were independent risk factors for the Gensini score. In the linear analysis, the Gensini score was negatively correlated with HbA1cTIR (<italic toggle="yes">&#946;</italic> = &#8722;0.629; <italic toggle="yes">r</italic> &lt; 0.001) and positively correlated with SD-HbA1c (<italic toggle="yes">&#946;</italic> = 0.271; <italic toggle="yes">r</italic> = 0.001) and CV-HbA1c (<italic toggle="yes">&#946;</italic> = 0.176; <italic toggle="yes">r</italic> = 0.033). After subgroup analysis, HbA1cTIR was a risk factor for the number of involved vessels. The Gensini score was negatively correlated with HbA1cTIR and positively correlated with SD-HbA1c at subgroups of subjects with a mean HbA1c &#8804; 7%.</p><p>
<bold>Conclusions:</bold> Our analysis indicates that HbA1c variability, especially HbA1cTIR, plays a role for the severity of CAD in patients with T2DM. HbA1c variability may provide additional information and require management even at the glycemic target.</p><p>
<bold>Translational Aspects:</bold> Studies have shown that HbA1c variability is related to cardiovascular complications. Further, we explore the correlation between HbA1c variability and the severity of CAD. HbA1c variability is a risk factor for coronary stenosis in T2DM. It may be a potential indicator reflecting glycemic control for the prevention and treatment of cardiovascular complications.</p></abstract><kwd-group kwd-group-type="Inspec"><title>Keywords</title><kwd>coronary heart disease</kwd><kwd>diabetic cardiovascular complications</kwd><kwd>glycosylated hemoglobin variability</kwd><kwd>HbA1c time in range</kwd><kwd>Type 2 diabetes mellitus</kwd></kwd-group><funding-group><award-group><funding-source>Science Foundation of Liaoning Science and Technology Department</funding-source><award-id>2023JH2/1017001195</award-id><award-id>2023JH2/101700125</award-id></award-group><award-group><funding-source>Clinical Research Project of Liaoning Diabetes Medical Nutrition Prevention Society</funding-source><award-id>LNSTNBYXYYFZXH-RS02A</award-id><award-id>LNSTNBYXYYFZXH-RS01B</award-id></award-group><award-group><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/501100015226">Shengjing Hospital</funding-source></award-group><award-group><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/501100001809">National Natural Science Foundation of China</funding-source><award-id>82200930</award-id><award-id>81700706</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>With the improvement of living standard, the prevalence of diabetes is increasing year by year. According to the latest epidemiological survey and research, the overall prevalence of diabetes in mainland China is 11.2%, of which Type 2 diabetes mellitus (T2DM) accounts for more than 90% [<xref rid="B1" ref-type="bibr">1</xref>]. Diabetes has become a global public health problem and danger to human health [<xref rid="B2" ref-type="bibr">2</xref>]. Compared with healthy individuals, patients with T2DM have a higher risk of cardiovascular disease [<xref rid="B3" ref-type="bibr">3</xref>], and cardiovascular complications are the leading cause of morbidity and mortality in these patients.</p><p>Glycosylated hemoglobin (HbA1c), as an indicator that reflects the average blood glucose level over the past 3 months, is recommended as a gold standard in blood glucose management. The American Diabetes Association (ADA) suggested that HbA1c &#8804; 7.0% may help delay the occurrence and development of diabetic complications [<xref rid="B4" ref-type="bibr">4</xref>]. However, recent clinical trials of intensive glycemic control in patients with Type 2 diabetes did not demonstrate beneficial effects on cardiovascular complications [<xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>]. This suggests that focusing only on HbA1c standard may have limitations [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>Previous studies have suggested that three main glycemic abnormalities, including hyperglycemia, hypoglycemia, and glucose variability (GV), may all accelerate the progression of cardiovascular complications in patients with T2DM [<xref rid="B9" ref-type="bibr">9</xref>]. In recent years, growing attention has been paid to the possible role of GV in the development of diabetic complications, particularly cardiovascular complications. Glucose variability includes short-term and long-term glucose variability. Previously, studies suggested that short-term glucose variability may be a risk factor for cardiovascular complications [<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B12" ref-type="bibr">12</xref>]. Other studies have suggested that long-term glucose variability, reflected by the variability of HbA1c and fasting blood glucose (FBG) over a period of time, can reflect the glucose variability over a longer period of time and is related to cardiovascular complications and all-cause mortality [<xref rid="B13" ref-type="bibr">13</xref>&#8211;<xref rid="B18" ref-type="bibr">18</xref>].</p><p>At present, glucose variability is mostly expressed by standard deviation (SD) and coefficient of variation (CV). The international consensus proposed that the time in range (TIR), defined as the percentage of time within 70&#8211;180&#8201;mg/dL (3.9&#8211;10&#8201;mmol/L), could reflect short-term glucose variability and blood glucose control and may minimize the risk of complications caused by hypoglycemia and hyperglycemia [<xref rid="B19" ref-type="bibr">19</xref>]. Prentice et al. suggested that HbA1cTIR, defined as the percentage of time within the target range of HbA1c, could reflect HbA1c variability and may be an independent risk factor for cardiovascular complications and all-cause mortality in patients with T2DM [<xref rid="B20" ref-type="bibr">20</xref>].</p><p>The severity of coronary artery disease (CAD) may affect the prognosis; however, studies on the relationship between long-term glucose variability and the severity of CAD in patients with T2DM are limited. Some studies suggested that the HbA1c may be associated with the severity of CAD in patients with T2DM [<xref rid="B21" ref-type="bibr">21</xref>&#8211;<xref rid="B23" ref-type="bibr">23</xref>]. However, some studies have also shown that HbA1c level is not related [<xref rid="B24" ref-type="bibr">24</xref>]. Currently, there are a variety of scoring systems used for quantitative analysis of coronary artery lesions, and the Gensini score is more commonly used in clinical practice. The Gensini score fully considers the number, location, and degree of stenosis of coronary artery lesions, which is a more scientific evaluation standard of coronary artery lesions. At the same time, this scoring system has also been widely used in related studies on the clinical outcomes of CAD [<xref rid="B25" ref-type="bibr">25</xref>]. In this study, we further explore the relationship between HbA1c variability and the severity of CAD (assessed by the Gensini score and the number of involved vessels) in order to improve the survival of patients with T2DM.</p></sec><sec id="sec2"><title>2. Methods</title><sec id="sec2.1"><title>2.1. Study Participants</title><p>We conducted a retrospective study of participants from patients with T2DM who underwent coronary arteriography (CAG) due to angina and were enrolled at Shengjing Hospital Affiliated with China Medical University from June 2015 to September 2022. The inclusion criteria for patients were as follows (<italic toggle="yes">n</italic> = 8437): (1) men and women over 18 years old, (2) patients diagnosed with T2DM according to the 2020 edition of the guideline for the prevention and treatment of Type 2 diabetes in China, and (3) patients who underwent coronary angiography. Exclusion criteria were as follows (<italic toggle="yes">n</italic> = 2223): (1) acute complications of diabetes mellitus (diabetic ketoacidosis, diabetic nonketotic hyperosmolar coma); (2) presence of major valve disease, myocarditis, malignant disease, hypoglycemia, and coma; and (3) hepatic and renal insufficiency. For calculation of HbA1c variability, subjects without at least five HbA1c measurements during the 4 years before under CAG (&#8805;&#8201;6 months apart) were further excluded (<italic toggle="yes">n</italic> = 6067). Thus, 147 patients comprised the final enrollment (as shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>). This study was approved by the ethics committee of Shengjing Hospital (ethics number 2022PS699K).</p></sec><sec id="sec2.2"><title>2.2. Clinical and Biochemical Data Assessments</title><p>The basic information and clinical characteristics of the participants were collected, including age, height, systolic blood pressure (SBP), diastolic blood pressure (DBP), the duration of diabetes, smoking habits, and use of insulin. The body mass index (BMI) was calculated based on height and weight. Besides HbA1c levels, we also collected other laboratory information, including levels of blood lipids such as triglycerides and low-density lipoprotein cholesterol (LDL-C) and estimated glomerular filtration rate (EGFR). After patients underwent selective CAG, the angiographic results were collected. Each coronary artery was displayed on at least two different planes.</p></sec><sec id="sec2.3"><title>2.3. Evaluation of HbA1c Variability</title><p>HbA1c variability was expressed as SD-HbA1c, CV-HbA1c, VIM-HbA1c, and HbA1cTIR during the 4 years before under CAG. We determined the SD-HbA1c of several HbA1c measurements for each patient. We calculated the CV-HbA1c, defined as CV=SD-HbA1c/meanHbA1c. In addition, we evaluated the variation independent of mean value (VIM-HbA1c), defined as 100 &#215; SD/mean <italic toggle="yes">&#946;</italic>, where <italic toggle="yes">&#946;</italic> is the regression coefficient, the natural log (ln) of the SD over the ln of the mean. In addition, we evaluated HbA1c variability by HbA1cTIR and the percentage of time that HbA1c levels were within the target range. To calculate HbA1cTIR [<xref rid="B20" ref-type="bibr">20</xref>], we first set the HbA1c target range for each patient individually according to expert consensus on HbA1c targets and management algorithms for Chinese adults with T2DM [<xref rid="B26" ref-type="bibr">26</xref>] (as shown in Table <xref rid="supplementary-material-1" ref-type="sec">S1</xref>). These values are updated every year, considering the age of the patients and the development of new conditions and diabetic complications. Finally, we computed HbA1cTIR as a percentage of time that HbA1c levels were within the target range [<xref rid="B20" ref-type="bibr">20</xref>]. In addition, SD-HbA1c, CV-HbA1c, and HBA1cTIR may reflect the variability and the mean level of long-term blood glucose levels. The application of TIR can help reduce the risk of hypoglycemia and hyperglycemia. And HbA1cVIM may reflect the variability of HBA1c and is not related to the mean level of HBA1c. Therefore, we also discuss the relationship between these two indicators and the severity of CAD in this article.</p></sec><sec id="sec2.4"><title>2.4. Assessment of Severity of CAD</title><p>We used two methods to evaluate the severity of CAD, the Gensini score and the number of involved vessels [<xref rid="B25" ref-type="bibr">25</xref>]. The number of involved vessels was characterized as 1-vessel disease, 2-vessel disease, and 3-vessel disease. We evaluated the Gensini score, which assigned the severity score based on the degree and location of stenosis based on previous publications. In detail, the narrowing was scored as 32 for 100% occluded artery, 16 for 91%&#8211;99%, 8 for 76%&#8211;90%, 4 for 51%&#8211;75%, 2 for 26%&#8211;50%, and 1 for 1%&#8211;25%. The score was then multiplied by a coefficient to indicate the functional importance of each segment. The coefficient was as follows: the left main coronary artery was five; the proximal left anterior descending artery and the proximal circumflex artery were 2.5; the middle left anterior descending artery was 1.5; the right coronary artery, the distal left anterior descending artery, the posterolateral artery, and the obtuse artery were 1.0; and the residual major segments were 0.5 [<xref rid="B25" ref-type="bibr">25</xref>]. Finally, the Gensini score was calculated by the sum of the integral of each coronary artery segment.</p></sec><sec id="sec2.5"><title>2.5. Statistical Methods</title><p>Descriptive data are summarized as median and interquartile range for continuous variables and percentages for categorical variables. All patients were divided into three groups according to the number of involved vessels: 1-vessel disease, 2-vessel disease, and 3-vessel disease. For normally distributed variables, differences in different groups were analyzed by analysis of variance (ANOVA). For nonnormally distributed continuous variables, differences were analyzed by the Mann&#8211;Whitney <italic toggle="yes">U</italic> test or the Kruskal&#8211;Wallis test. Then, we divided all patients into three groups according to the Gensini score, and we analyzed the differences between the characteristics of participants in the different groups.</p><p>Further, we divided the patients according to tertiles of HbA1c variability. We analyzed the difference in the number of involved vessels and Gensini scores between different groups.</p><p>The association between HbA1c variability and risk of the severity of CAD was investigated through multivariate logistic regression analyses. Logistic regression analysis was used to estimate odds ratios (ORs) of HbA1c variability and the number of involved vessels. In Model 1, no factors were adjusted. Model 2 was adjusted for sex, age, duration of diabetes, SBP, DBP, LDL, and the use of insulin. Model 3 was adjusted for sex, age, duration of diabetes, SBP, DBP, LDL, use of insulin, and HbA1c level. Logistic regression analysis was used to estimate ORs of HbA1c variability and the Gensini score. In Model 1, no factors were adjusted. In Model 2, sex, age, duration of diabetes, SBP, DBP, LDL, and the use of insulin were adjusted. In Model 3, sex, age, duration of diabetes, SBP, DBP LDL, use of insulin, and HbA1c were adjusted. Linear regression analysis was performed to determine the relationship between HbA1c variability and the Gensini score. To avoid collinearity between these parameters, each parameter had been in separated model.</p><p>Subjects were also divided into two subgroups, based on the average HbA1c levels &#8804; 7% or &gt;&#8201;7%. The relationship between HbA1c variability and the number of involved vessels was analyzed by multivariate regression. The relationship between HbA1c variability and the Gensini score was analyzed by linear regression and multivariate regression in the different subgroups.</p><p>All analyses were performed using SPSS version 25.0 for Windows (SPSS Corporation, Chicago, Illinois, USA). A <italic toggle="yes">r</italic>-value of &lt;&#8201;0.05 was considered statistically significant. Continuous variables are presented as median (interquartile range) or mean &#177; SD and categorical data are summarized as frequencies (percentages). For normally distributed variables, differences in different groups were analyzed by ANOVA. For nonnormally distributed continuous variables, differences were analyzed by the Mann&#8211;Whitney <italic toggle="yes">U</italic> test or the Kruskal&#8211;Wallis test.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Basic Characteristics of the Study Population</title><p>From the 8437 T2DM patients under coronary angiography in the database, we identified all subjects with at least five measurements of HbA1c taken over a period of 4 years before under CAG (<italic toggle="yes">n</italic> = 147). The mean number of HbA1c tests in the entire population was 5.41.</p><p>Compared with patients with 1-vessel disease, the duration of diabetes, use of insulin, SD-HbA1c, and HbA1c were increased, and HbA1cTIR was decreased in patients with multiple vessel disease. There were no significant differences in age, sex, smoking habits, SBP, DBP, LDL, triglyceride, EGFR, BMI, the number of HbA1c measurements CV-HbA1c, and VIM-HbA1c (as shown in <xref rid="tab1a" ref-type="table">Table 1(a)</xref>).</p><p>Compared with the lowest quartile (Q1) groups of the Gensini score, disease duration, insulin use, SD-HbA1c, and CV-HbA1c were increased, and HbA1cTIR was decreased in higher groups (as shown in <xref rid="tab1b" ref-type="table">Table 1(b)</xref>). There were no significant differences in age, sex, smoking habits, SBP, DBP, BMI, the number of HbA1c, triglyceride, EGFR, VIM-HbA1c, or LDL between the groups.</p></sec><sec id="sec3.2"><title>3.2. Associations of HbA1c Variability With Severity of CAD</title><p>Coronary artery stenosis was compared in subjects stratified by tertiles of HbA1C variability. The percentages of 3-vessel, multivessel, and Gensini scores decreased with increasing tertiles of HbA1cTIR. Gensini scores increased with increasing tertiles of SD-HbA1c and CV-HbA1c (as shown in Table <xref rid="supplementary-material-1" ref-type="sec">S2</xref>).</p><p>Univariate and multivariate regression analyses were performed to analyze the association between the coronary artery stenosis and different measures of HbA1c variability. In univariate logistics analysis, HbA1cTIR (OR, 0.09; IQR: 0.03, 0.24; <italic toggle="yes">r</italic> &lt; 0.001) and SD-HbA1c (OR, 2.59; IQR: 1.32, 5.11; <italic toggle="yes">r</italic> = 0.007) were risk factors for the number of involved vessels. After adjusting risk factors, such as sex, age, duration, HbA1c, SBP, DBP, LDL, and use of insulin, HbA1cTIR (OR, 0.13; IQR: 0.04, 0.41; <italic toggle="yes">r</italic> &lt; 0.001) and VIM-HbA1c (OR, 2.60; IQR: 1.15, 5.90; <italic toggle="yes">r</italic> = 0.026) were independent risk factors for the number of involved vessels, and the difference was statistically significant (as shown in <xref rid="tab2" ref-type="table">Table 2</xref>).</p><p>In univariate logistics analysis, HbA1cTIR (OR, 0.007; IQR: 0.002, 0.03; <italic toggle="yes">r</italic> &lt; 0.001), SD-HbA1c (OR, 4.15; IQR: 2.03, 8.48; <italic toggle="yes">r</italic> &lt; 0.001), CV-HbA1c (OR, 1.42; IQR: 1.08, 1.86; <italic toggle="yes">r</italic> = 0.004), and VIM-HbA1c (OR, 2.10; IQR: 1.01, 4.36; <italic toggle="yes">r</italic> = 0.036) were risk factors for the Gensini score. After adjusting risk factors, such as sex, age, duration, HbA1c, SBP, DBP, LDL, and use of insulin using HbA1cTIR (OR, 0.01; IQR: 0.002, 0.04; <italic toggle="yes">r</italic> &lt; 0.001), SD-HbA1c (OR, 4.12; IQR: 1.64, 10.35; <italic toggle="yes">r</italic> = 0.001), CV-HbA1c (OR, 1.41; IQR: 1.04, 1.92; <italic toggle="yes">r</italic> = 0.007), and VIM-HbA1c (OR, 3.26; IQR: 1.43, 7.47; <italic toggle="yes">r</italic> = 0.003) were independent risk factors for the Gensini score, and the difference was statistically significant (as shown in Table <xref rid="supplementary-material-1" ref-type="sec">S3</xref>).</p><p>Univariate and multivariate linear regression analyses were performed to analyze the association between the Gensini score and HbA1c variability. Univariable linear regression analysis showed that Gensini score was negatively correlated with HbA1cTIR (<italic toggle="yes">&#946;</italic> = &#8722;0.629; <italic toggle="yes">r</italic> &lt; 0.001) and positively correlated with SD-HbA1c (<italic toggle="yes">&#946;</italic> = 0.271; <italic toggle="yes">r</italic> = 0.001), CV-HbA1c (<italic toggle="yes">&#946;</italic> = 0.176; <italic toggle="yes">r</italic> = 0.033), HbA1c (<italic toggle="yes">&#946;</italic> = 0.29; <italic toggle="yes">r</italic> &lt; 0.001), and duration (<italic toggle="yes">&#946;</italic> = 0.245; <italic toggle="yes">r</italic> = 0.002). (as shown in <xref rid="tab3" ref-type="table">Table 3</xref> and <xref rid="fig2" ref-type="fig">Figure 2</xref>). After adjusting for factors such as age, sex, duration, SBP, DBP, LDL, insulin use, and HbA1c, the Gensini score was negatively correlated with HbA1cTIR (<italic toggle="yes">&#946;</italic> = &#8722;0.576; <italic toggle="yes">r</italic> &lt; 0.001) and positively correlated with SD-HbA1c (<italic toggle="yes">&#946;</italic> = 0.217; <italic toggle="yes">r</italic> = 0.024) and CV-HbA1c (<italic toggle="yes">&#946;</italic> = 0.160; <italic toggle="yes">r</italic> = 0.031) (as shown in <xref rid="tab3" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3.3"><title>3.3. Subgroup Analysis of the Relationship Between HbA1c Variability and Severity of CAD</title><p>To assess if GV was associated with the degree of coronary artery stenosis also in subjects at target (AT) HbA1c, we analyzed the subgroups of patients with mean HbA1c &#8804; 7% (AT) or &gt;&#8201;7% (not at target [NAT]). After subgroup analysis, in the HbA1c &#8804; 7% group, HbA1cTIR (OR, 0.008; IQR: 0.001, 0.08; <italic toggle="yes">r</italic> &lt; 0.001) was an independent risk factor for the number of involved vessels. The Gensini score was negatively correlated with HbA1cTIR (<italic toggle="yes">&#946;</italic> = &#8722;0.713, <italic toggle="yes">r</italic> &lt; 0.001) (as shown in Tables <xref rid="supplementary-material-1" ref-type="sec">S4a</xref> and <xref rid="supplementary-material-1" ref-type="sec">S4b</xref>). At HbA1c &gt; 7%, the Gensini score was negatively correlated with HbA1cTIR (<italic toggle="yes">&#946;</italic> = &#8722;0.576; <italic toggle="yes">r</italic> &lt; 0.001) and positively correlated with SD-HbA1c (<italic toggle="yes">&#946;</italic> = 0.215; <italic toggle="yes">r</italic> = 0.037) (as shown in Tables <xref rid="supplementary-material-1" ref-type="sec">S4c</xref> and <xref rid="supplementary-material-1" ref-type="sec">S4d</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The primary findings of our study are as follows. First, the Gensini score was negatively correlated with HbA1cTIR and positively correlated with CV-HbA1c and SD-HbA1c in patients with T2DM. Second, we found that HbA1cTIR and VIM-HbA1c are independent risk factors for the number of involved vessels. Third, HbA1cTIR is a risk factor for the severity of CAD in patients with T2DM, regardless of whether the mean blood glucose is within the target (HbA1c &#8804; 7%). Overall, our results support that HbA1c variability, especially HbA1cTIR, may be related to the severity of CAD in patients with T2DM and is worthy of attention in blood glucose management.</p><p>In recent years, a number of studies have shown the association between long-term glucose variability and cardiovascular complications [<xref rid="B13" ref-type="bibr">13</xref>&#8211;<xref rid="B18" ref-type="bibr">18</xref>]. Meta-analysis reports also suggest that long-term glucose variability in patients with T2DM is associated with almost all cardiovascular complications. Although the mean level remains important for the prevention of cardiovascular events in patients with T2DM, previous studies suggested that HbA1c variability is an independent risk factor for cardiovascular disease regardless of being at the glycemic target [<xref rid="B27" ref-type="bibr">27</xref>]. In addition, Yang et al. [<xref rid="B28" ref-type="bibr">28</xref>] considered that HbA1c variability was an independent predictor of the incidence of in-stent restenosis in patients with Type 2 diabetes after stent implantation.</p><p>All the above studies suggested that long-term glucose variabilities were independent risk factors for cardiovascular disease in patients with T2DM, and targets in blood glucose management need to focus on both stability and absolute level of HbA1c [<xref rid="B29" ref-type="bibr">29</xref>]. However, the relationship between HbA1c variability and severity of CAD in patients with T2DM is not clear. Our experiment further explored the relationship between the HbA1c variability and the severity of CAD in patients with T2DM. Our results suggested that in patients with T2DM, HbA1cTIR and SD-HbA1c were risk factors for the number of involved vessels. After adjusting the risk factors, we found that the HbA1cTIR and VIM-HbA1c were independent risk factors for the number of involved vessels. After adjusting for related risk factors such as HbA1c, the logistics results still suggest that HbA1c variability was an independent risk factor for the Gensini score. After linear regression analysis, the results suggested that SD-HbA1c and CV-HbA1c were positively correlated with the Gensini score, while HbA1cTIR was negatively correlated with the Gensini score. Both the Gensini score and the number of involved vessels are indicators reflecting the severity of CAD. Our study has shown that the HbA1c variability may be a risk factor for the severity of CAD in patients with T2DM.</p><p>To analyze the reasons, it may be that patients with higher HbA1c variability may have poor management of blood glucose and poor basic vascular condition. In addition, hypoglycemia may mediate the association between HbA1c variability and severity of CAD. Recently, studies have also reported that long-term glucose variability is related to cardiovascular disease in patients within the target of HbA1c [<xref rid="B30" ref-type="bibr">30</xref>]. Other study suggests that glucose variability may predict the risk of hypoglycemia, especially in patients receiving intensive therapy [<xref rid="B31" ref-type="bibr">31</xref>]. After subgroup analysis, our study also suggests that HbA1cTIR was a risk factor for the severity of coronary artery stenosis in patients within the target of HbA1c [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. Our research suggested that HbA1c variability is related to the severity of CAD in patients with T2DM. Thus, in addition to the mean blood glucose, long-term stability is necessary for patients with diabetes in clinical practice. In addition, our study also suggested that setting the HbA1c target range for each patient individually may also be necessary for patients with diabetes in clinical practice. For patients with T2DM, we suggested the patients to maintain long-term stability of blood glucose and achieve individual target by lifestyle education and pharmacological tools.</p><p>The underlying mechanism of the relationship between HbA1c variability and cardiovascular disease in patients with T2DM is unknown. Oxidative stress, low-grade inflammation, and endothelial dysfunction may be the key drivers. Previous studies suggested that compared with chronic hyperglycemia, glucose variability is more likely to include vascular damage and endothelial dysfunction mainly mediated by oxidative stress [<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>]. Tateishi et al. suggest that GV is significantly associated with coronary rather than peripheral endothelial dysfunction in patients with CAD, which may be a part of underlying mechanisms of coronary atherosclerosis [<xref rid="B36" ref-type="bibr">36</xref>]. Glucose variability may lead to the accumulation of glycolytic intermediates, including the activation of the polyol pathway, advanced glycation end products, protein kinase C pathway, and hexosamine pathway, and may also participate in the damage of endothelial cells [<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>]. Some studies have found that the oxidative stress of protein kinase C may cause the generation of reactive oxygen species (ROS) induced by activation. Vascular cell growth and apoptosis, extracellular matrix synthesis, and changes in vascular homeostasis further promote the development of atherosclerosis [<xref rid="B38" ref-type="bibr">38</xref>]. Long-term GV may also cause irreversible epigenetic modifications, resulting in <italic toggle="yes">&#946;</italic>-cell dysfunction. Finally, hypoglycemia may lead to an increased risk of cardiovascular disease because of the release of inflammatory cytokines, increased platelet activation and endothelial dysfunction, and sympathetic-adrenal response (which may lead to arrhythmia and increased cardiac workload) [<xref rid="B39" ref-type="bibr">39</xref>&#8211;<xref rid="B41" ref-type="bibr">41</xref>]. Thus, adverse cardiovascular outcomes may result from a combination of these risk factors.</p><p>This study explored the relationship between HbA1c variability and the severity of CAD in patients with T2DM, which was rare in previous studies. For patients with diabetes, HbA1c is important in the blood glucose management. Our study suggested that in addition to mean HbA1c, HbA1c variability is also essential. The calculation and management for HbA1c variability are also convenient. At the same time, a relatively new indicator, HbA1cTIR, was introduced to minimize the risk of hypoglycemia, hyperglycemia, and complications during blood glycemic management. Thus, our study is rational and positive in clinical application.</p><p>This study has several limitations. First, despite our effort to ensure consistency in screening intervals, the number, frequency, and interval of HbA1c measurements vary from patient to patient. Second, our retrospective analysis selected patients who received treatment for coronary heart disease. Thus, many patients did not regularly accept diabetes management before this treatment and did not meet our requirements for HbA1c measurements, leading to a small sample size. Due to the same reason, our study lacks data on the prevalence of usage of the most relevant groups of medications and lifestyle-related surveys. In the further prospective studies, we will provide the prevalence of usage of the most relevant groups of medications. Further prospective studies are needed to investigate the possible causal relationship between the HbA1c variability and the severity of CAD in patients with T2DM and to calculate cut-off values for the HbA1c variability parameter. So that may help to explore whether the HbA1c variability is a valuable therapeutic target.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>In conclusion, our findings suggest that HbA1c variability, especially HbA1cTIR, may be associated with the severity of coronary artery stenosis in patients with T2DM. This study suggests that in addition to mean HbA1c, long-term blood glucose variability is also important in blood glucose management, which deserves our attention and further exploration. In addition, these results support the necessity for using a personalized approach to HbA1c target and stability, especially in older patients with diabetes.</p></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge Runyu Du for providing intellectual support and Danyang Li for providing technical assistance.</p></ack><sec sec-type="data-availability"><title>Data Availability Statement</title><p>The patient information data used to support the findings of this study are restricted by the Medical Ethics Committee of Shengjing Hospital affiliated to China Medical University in order to protect patient privacy. Data are available from Na Wu, <email>3441535223@qq.com</email>, for researchers who meet the criteria for access to confidential data.</p></sec><sec sec-type="ethics-statement"><title>Ethics Statement</title><p>This study was approved by the ethics committee of Shengjing Hospital (ethics number: 2022PS699K).</p></sec><sec><title>Disclosure</title><p>None of the article contents are under consideration for publication in any other journal or have been published in any journal. No portion of the text has been copied from other material in the literature (unless in quotation marks, with citation). I am aware that it is the author's responsibility to obtain permission for any figures or tables reproduced from any prior publications and to cover fully any costs involved. Such permission must be obtained prior to final acceptance.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec><title>Author Contributions</title><p>Xinyan Liu is responsible for writing the paper, consulting materials, and designing experiments. Xiyao Yang is responsible for writing, revising, and submitting the paper. Na Wu is responsible for providing guidance and writing and revising the manuscript. Xinyan Liu and Xiyao Yang contributed to the work equally and should be regarded as co-first authors. The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. All authors have participated in the work and have reviewed and agreed with the content of the article.</p></sec><sec><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (Nos. 81700706 and 82200930), the 345 Talent Project of Shengjing Hospital, the Clinical Research Project of Liaoning Diabetes Medical Nutrition Prevention Society (Nos. LNSTNBYXYYFZXH-RS01B and LNSTNBYXYYFZXH-RS02A), and the Science Foundation of Liaoning Science and Technology Department (Nos. 2023JH2/101700125 and 2023JH2/1017001195).</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supporting Information</title><supplementary-material id="supp-1" position="float" content-type="local-data" orientation="portrait"><label>Supporting Information</label><caption><p>Additional supporting information can be found online in the Supporting Information section. Table S1 HbA1c targets different populations. Table S2 Coronary artery stenosis according to tertile of HbA1c variability. Table S3 Multivariate analysis for the Gensini score. Table S4a HbA1c &#8804; 7% multivariate analysis for the number of involved vessels.Table S4b HbA1c &#8804; 7% linear regression analyses for the Gensini score. Table S4c HbA1c &gt; 7% multivariate analysis for the number of involved vessels. Table S4d HbA1c &gt; 7% linear regression analyses for the Gensini score.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="9958586.f1.doc" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><collab>Chinese Diabetes Society</collab><article-title>Guidelines for the prevention and control of type 2 diabetes in China (2020 Edition)</article-title><source><italic toggle="yes">Chinese Journal of Practical Internal Medicine</italic></source><year>2021</year><volume>41</volume><issue>5</issue><fpage>482</fpage><lpage>548</lpage></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmet</surname><given-names>P. Z.</given-names></name><name name-style="western"><surname>Magliano</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J. E.</given-names></name></person-group><article-title>Diabetes: a 21st century challenge</article-title><source><italic toggle="yes">The Lancet Diabetes and Endocrinology</italic></source><year>2014</year><volume>2</volume><issue>1</issue><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(13)70112-8</pub-id><pub-id pub-id-type="other">2-s2.0-84890247834</pub-id><pub-id pub-id-type="pmid">24622669</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayward</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Reaven</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Wiitala</surname><given-names>W. L.</given-names></name><etal/></person-group><article-title>Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2015</year><volume>372</volume><issue>23</issue><fpage>2197</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1414266</pub-id><pub-id pub-id-type="other">2-s2.0-84930532577</pub-id><pub-id pub-id-type="pmid">26039600</pub-id></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh-Swaby</surname><given-names>O. R.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Leiter</surname><given-names>L. A.</given-names></name><etal/></person-group><article-title>Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials</article-title><source><italic toggle="yes">The Lancet Diabetes and Endocrinology</italic></source><year>2020</year><volume>8</volume><issue>5</issue><fpage>418</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(20)30038-3</pub-id><pub-id pub-id-type="pmid">32333878</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><collab>American Diabetes Association</collab><article-title>2. Classification and diagnosis of Diabetes:Standards of medical care in diabetes-2019</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2019</year><volume>42</volume><issue>Supplement 1</issue><fpage>S13</fpage><lpage>S28</lpage><pub-id pub-id-type="doi">10.2337/dc19-S002</pub-id><pub-id pub-id-type="other">2-s2.0-85058743213</pub-id><pub-id pub-id-type="pmid">30559228</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>D'Alessio</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Fradkin</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2018</year><volume>41</volume><issue>12</issue><fpage>2669</fpage><lpage>2701</lpage><pub-id pub-id-type="doi">10.2337/dci18-0033</pub-id><pub-id pub-id-type="other">2-s2.0-85056802117</pub-id><pub-id pub-id-type="pmid">30291106</pub-id><pub-id pub-id-type="pmcid">PMC6245208</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoungas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chalmers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Follow-up of blood-pressure lowering and glucose control in type 2 diabetes</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2014</year><volume>371</volume><issue>15</issue><fpage>1392</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1407963</pub-id><pub-id pub-id-type="other">2-s2.0-84907862963</pub-id><pub-id pub-id-type="pmid">25234206</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duckworth</surname><given-names>W.</given-names></name><name name-style="western"><surname>Abraira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Glucose control and vascular complications in veterans with type 2 diabetes</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2009</year><volume>360</volume><issue>2</issue><fpage>129</fpage><lpage>139</lpage><comment>Erratum in: N Engl J med. 2009 Sep 3; 361 (10): 1028. Erratum in: N Engl J med. 2009 Sep 3; 361 (10): 1024-5</comment><pub-id pub-id-type="doi">10.1056/NEJMoa0808431</pub-id><pub-id pub-id-type="other">2-s2.0-58149389215</pub-id><pub-id pub-id-type="pmid">19092145</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><collab>Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group</collab><article-title>Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2016</year><volume>39</volume><issue>5</issue><fpage>686</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.2337/dc15-1990</pub-id><pub-id pub-id-type="other">2-s2.0-84964776844</pub-id><pub-id pub-id-type="pmid">26861924</pub-id><pub-id pub-id-type="pmcid">PMC4839174</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Association between glycemic variability and major adverse cardiovascular and cerebrovascular events (MACCE) in patients with acute coronary syndrome during 30-day follow-up</article-title><source><italic toggle="yes">Clinica Chimica Acta</italic></source><year>2017</year><volume>466</volume><fpage>162</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2017.01.022</pub-id><pub-id pub-id-type="other">2-s2.0-85010825754</pub-id><pub-id pub-id-type="pmid">28111271</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsutani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iuchi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report</article-title><source><italic toggle="yes">Cardiovascular Diabetology</italic></source><year>2018</year><volume>17</volume><issue>1</issue><fpage>p. 36</fpage><pub-id pub-id-type="doi">10.1186/s12933-018-0683-2</pub-id><pub-id pub-id-type="other">2-s2.0-85043467553</pub-id><pub-id pub-id-type="pmid">29514695</pub-id><pub-id pub-id-type="pmcid">PMC5840775</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kirigaya</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome</article-title><source><italic toggle="yes">Cardiovascular Diabetology</italic></source><year>2018</year><volume>17</volume><issue>1</issue><fpage>p. 116</fpage><pub-id pub-id-type="doi">10.1186/s12933-018-0761-5</pub-id><pub-id pub-id-type="other">2-s2.0-85051719673</pub-id><pub-id pub-id-type="pmid">30121076</pub-id><pub-id pub-id-type="pmcid">PMC6098663</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zoungas</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2014</year><volume>37</volume><issue>8</issue><fpage>2359</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.2337/dc14-0199</pub-id><pub-id pub-id-type="other">2-s2.0-84905001392</pub-id><pub-id pub-id-type="pmid">24812434</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nemeth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hapca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>E. R.</given-names></name></person-group><article-title>Visit-to-visit HbA<sub>1c</sub> variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2020</year><volume>43</volume><issue>2</issue><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.2337/dc19-0823</pub-id><pub-id pub-id-type="pmid">31727686</pub-id></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>C. R. L.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Moram</surname><given-names>C. B. M.</given-names></name><name name-style="western"><surname>Salles</surname><given-names>G. F.</given-names></name></person-group><article-title>Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study</article-title><source><italic toggle="yes">Cardiovascular Diabetology</italic></source><year>2018</year><volume>17</volume><issue>1</issue><fpage>p. 33</fpage><pub-id pub-id-type="doi">10.1186/s12933-018-0677-0</pub-id><pub-id pub-id-type="other">2-s2.0-85042600331</pub-id><pub-id pub-id-type="pmid">29477146</pub-id><pub-id pub-id-type="pmcid">PMC6389075</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Prognostic significance of long-term HbA<sub>1c</sub> variability for all-cause mortality in the ACCORD trial</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2020</year><volume>43</volume><issue>6</issue><fpage>1185</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.2337/dc19-2589</pub-id><pub-id pub-id-type="pmid">32229597</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>H. T.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>S.</given-names></name></person-group><article-title>Comparative predictive ability of visit-to-visit HbA<sub>1c</sub> variability measures for microvascular disease risk in type 2 diabetes</article-title><source><italic toggle="yes">Cardiovascular Diabetology</italic></source><year>2020</year><volume>19</volume><issue>1</issue><fpage>p. 105</fpage><pub-id pub-id-type="doi">10.1186/s12933-020-01082-9</pub-id><pub-id pub-id-type="pmid">32631323</pub-id><pub-id pub-id-type="pmcid">PMC7339461</pub-id></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghouse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Skov</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Kanters</surname><given-names>J. K.</given-names></name><etal/></person-group><article-title>Visit-to-visit variability of hemoglobin A1c in people without diabetes and risk of major adverse cardiovascular events and all-cause mortality</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2019</year><volume>42</volume><issue>1</issue><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.2337/dc18-1396</pub-id><pub-id pub-id-type="other">2-s2.0-85059081042</pub-id><pub-id pub-id-type="pmid">30352898</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battelino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Danne</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bergenstal</surname><given-names>R. M.</given-names></name><etal/></person-group><article-title>Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2019</year><volume>42</volume><issue>8</issue><fpage>1593</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.2337/dci19-0028</pub-id><pub-id pub-id-type="other">2-s2.0-85066997802</pub-id><pub-id pub-id-type="pmid">31177185</pub-id><pub-id pub-id-type="pmcid">PMC6973648</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prentice</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Increased hemoglobin A1c time in range reduces adverse health outcomes in older adults with diabetes</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2021</year><volume>44</volume><issue>8</issue><fpage>1750</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.2337/dc21-0292</pub-id><pub-id pub-id-type="pmid">34127496</pub-id><pub-id pub-id-type="pmcid">PMC8385473</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravipati</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aronow</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sujata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saulle</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>M. B.</given-names></name></person-group><article-title>Association of hemoglobin A1c level with the severity of coronary artery disease in patients with diabetes mellitus</article-title><source><italic toggle="yes">The American Journal of Cardiology</italic></source><year>2006</year><volume>97</volume><issue>7</issue><fpage>968</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2005.10.039</pub-id><pub-id pub-id-type="other">2-s2.0-33645076542</pub-id><pub-id pub-id-type="pmid">16563896</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wattanakit</surname><given-names>K.</given-names></name><name name-style="western"><surname>Steffes</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sharrett</surname><given-names>A. R.</given-names></name></person-group><article-title>HbA<sub>1c</sub> and peripheral arterial disease in Diabetes</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2006</year><volume>29</volume><issue>4</issue><fpage>877</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.2337/diacare.29.04.06.dc05-2018</pub-id><pub-id pub-id-type="other">2-s2.0-33746330460</pub-id><pub-id pub-id-type="pmid">16567831</pub-id></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engoren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Habib</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Zacharias</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The prevalence of elevated hemoglobin A1c in patients undergoing coronary artery bypass surgery</article-title><source><italic toggle="yes">Journal of Cardiothoracic Surgery</italic></source><year>2008</year><volume>3</volume><issue>1</issue><fpage>p. 63</fpage><pub-id pub-id-type="doi">10.1186/1749-8090-3-63</pub-id><pub-id pub-id-type="other">2-s2.0-58149345725</pub-id><pub-id pub-id-type="pmid">19025628</pub-id><pub-id pub-id-type="pmcid">PMC2613378</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Hemoglobin A1c level is not related to the severity of atherosclerosis in patients with acute coronary syndrome</article-title><source><italic toggle="yes">Disease Markers</italic></source><year>2015</year><volume>2015</volume><fpage>5</fpage><pub-id pub-id-type="publisher-id">192108</pub-id><pub-id pub-id-type="doi">10.1155/2015/192108</pub-id><pub-id pub-id-type="other">2-s2.0-84938276764</pub-id><pub-id pub-id-type="publisher-id">192108</pub-id><pub-id pub-id-type="pmcid">PMC4519528</pub-id><pub-id pub-id-type="pmid">26257459</pub-id></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>D.</given-names></name></person-group><article-title>Expert consensus on glycated hemoglobin A1C targets and management algorithm for Chinese adults with type 2 diabetes</article-title><source><italic toggle="yes">China Medical Abstracts</italic></source><year>2020</year><volume>37</volume><issue>2</issue><fpage>p. 76</fpage></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gensini</surname><given-names>G. G.</given-names></name></person-group><article-title>A more meaningful scoring system for determining the severity of coronary heart disease</article-title><source><italic toggle="yes">The American Journal of Cardiology</italic></source><year>1983</year><volume>51</volume><issue>3</issue><fpage>p. 606</fpage><pub-id pub-id-type="doi">10.1016/S0002-9149(83)80105-2</pub-id><pub-id pub-id-type="other">2-s2.0-0020701346</pub-id><pub-id pub-id-type="pmid">6823874</pub-id></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The scope of HbA<sub>1c</sub> variability and risk of vascular complications among patients with type 2 diabetes: a systematic review and meta-analysis of prospective studies</article-title><source><italic toggle="yes">Hormone and Metabolic Research</italic></source><year>2022</year><volume>54</volume><issue>2</issue><fpage>94</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1055/a-1730-4904</pub-id><pub-id pub-id-type="pmid">35130570</pub-id></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Visit-to-visit HbA<sub>1c</sub> variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention</article-title><source><italic toggle="yes">Cardiovascular Diabetology</italic></source><year>2020</year><volume>19</volume><issue>1</issue><fpage>p. 133</fpage><pub-id pub-id-type="doi">10.1186/s12933-020-01111-7</pub-id><pub-id pub-id-type="pmid">32887588</pub-id><pub-id pub-id-type="pmcid">PMC7472579</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>Implications of fasting plasma glucose variability on the risk of incident peripheral artery disease in a population without diabetes: a nationwide population-based cohort study</article-title><source><italic toggle="yes">Cardiovascular Diabetology</italic></source><year>2022</year><volume>21</volume><issue>1</issue><fpage>p. 15</fpage><pub-id pub-id-type="doi">10.1186/s12933-022-01448-1</pub-id><pub-id pub-id-type="pmid">35101050</pub-id><pub-id pub-id-type="pmcid">PMC8805289</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceriello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lucisano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Prattichizzo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>HbA<sub>1c</sub> variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target</article-title><source><italic toggle="yes">Cardiovascular Diabetology</italic></source><year>2022</year><volume>21</volume><issue>1</issue><fpage>p. 13</fpage><pub-id pub-id-type="doi">10.1186/s12933-022-01445-4</pub-id><pub-id pub-id-type="pmid">35073913</pub-id><pub-id pub-id-type="pmcid">PMC8788128</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noyes</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Soto-Pedre</surname><given-names>E.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>E. R.</given-names></name></person-group><article-title>Characteristics of people with high visit-to-visit glycaemic variability in type 2 diabetes</article-title><source><italic toggle="yes">Diabetic Medicine</italic></source><year>2018</year><volume>35</volume><issue>2</issue><fpage>262</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1111/dme.13435</pub-id><pub-id pub-id-type="other">2-s2.0-85040700189</pub-id><pub-id pub-id-type="pmid">28755478</pub-id><pub-id pub-id-type="pmcid">PMC5811920</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pieber</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Marso</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>D. K.</given-names></name><etal/></person-group><article-title>DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality</article-title><source><italic toggle="yes">Diabetologia</italic></source><year>2018</year><volume>61</volume><issue>1</issue><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4422-0</pub-id><pub-id pub-id-type="other">2-s2.0-85029473387</pub-id><pub-id pub-id-type="pmid">28913543</pub-id><pub-id pub-id-type="pmcid">PMC6002964</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farabi</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Carley</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>L.</given-names></name></person-group><article-title>Impact of exercise on diurnal and nocturnal markers of glycaemic variability and oxidative stress in obese individuals with type 2 diabetes or impaired glucose tolerance</article-title><source><italic toggle="yes">Diabetes &amp; Vascular Disease Research</italic></source><year>2015</year><volume>12</volume><issue>5</issue><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1177/1479164115579003</pub-id><pub-id pub-id-type="other">2-s2.0-84938684452</pub-id><pub-id pub-id-type="pmid">25994591</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monnier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Colette</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mas</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy</article-title><source><italic toggle="yes">Diabetologia</italic></source><year>2010</year><volume>53</volume><issue>3</issue><fpage>562</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1007/s00125-009-1574-6</pub-id><pub-id pub-id-type="other">2-s2.0-77949263068</pub-id><pub-id pub-id-type="pmid">19890623</pub-id></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>I. C.</given-names></name></person-group><article-title>Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus</article-title><source><italic toggle="yes">Acta Diabetologica</italic></source><year>2012</year><volume>49</volume><issue>Supplement 1</issue><fpage>S171</fpage><lpage>S177</lpage><pub-id pub-id-type="doi">10.1007/s00592-012-0398-x</pub-id><pub-id pub-id-type="other">2-s2.0-84878893878</pub-id><pub-id pub-id-type="pmid">22547264</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tateishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kitahara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>Y.</given-names></name></person-group><article-title>Impact of glycemic variability on coronary and peripheral endothelial dysfunction in patients with coronary artery disease</article-title><source><italic toggle="yes">Journal of Cardiology</italic></source><year>2022</year><volume>79</volume><issue>1</issue><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2021.08.009</pub-id><pub-id pub-id-type="pmid">34456069</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosentino-Gomes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rocco-Machado</surname><given-names>N.</given-names></name><name name-style="western"><surname>Meyer-Fernandes</surname><given-names>J. R.</given-names></name></person-group><article-title>Cell signaling through protein kinase C oxidation and activation</article-title><source><italic toggle="yes">International Journal of Molecular Sciences</italic></source><year>2012</year><volume>13</volume><issue>9</issue><fpage>10697</fpage><lpage>10721</lpage><pub-id pub-id-type="doi">10.3390/ijms130910697</pub-id><pub-id pub-id-type="other">2-s2.0-84866914984</pub-id><pub-id pub-id-type="pmid">23109817</pub-id><pub-id pub-id-type="pmcid">PMC3472709</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gude</surname><given-names>F.</given-names></name><name name-style="western"><surname>D&#237;az-Vidal</surname><given-names>P.</given-names></name><name name-style="western"><surname>R&#250;a-P&#233;rez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Glycemic variability and its association with demographics and lifestyles in a general adult population</article-title><source><italic toggle="yes">Journal of Diabetes Science and Technology</italic></source><year>2017</year><volume>11</volume><issue>4</issue><fpage>780</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1177/1932296816682031</pub-id><pub-id pub-id-type="other">2-s2.0-85023195732</pub-id><pub-id pub-id-type="pmid">28317402</pub-id><pub-id pub-id-type="pmcid">PMC5588820</pub-id></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratter</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Rooijackers</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Tack</surname><given-names>C. J.</given-names></name><etal/></person-group><article-title>Proinflammatory effects of hypoglycemia in humans with or without diabetes</article-title><source><italic toggle="yes">Diabetes</italic></source><year>2017</year><volume>66</volume><issue>4</issue><fpage>1052</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.2337/db16-1091</pub-id><pub-id pub-id-type="other">2-s2.0-85019617340</pub-id><pub-id pub-id-type="pmid">28115398</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gogitidze Joy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hedrington</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Briscoe</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Tate</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Ertl</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>S. N.</given-names></name></person-group><article-title>Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals</article-title><source><italic toggle="yes">Diabetes Care</italic></source><year>2010</year><volume>33</volume><issue>7</issue><fpage>1529</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.2337/dc09-0354</pub-id><pub-id pub-id-type="other">2-s2.0-77958192003</pub-id><pub-id pub-id-type="pmid">20587723</pub-id><pub-id pub-id-type="pmcid">PMC2890354</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reno</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Daphna-Iken</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>VanderWeele</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jethi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>S. J.</given-names></name></person-group><article-title>Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation</article-title><source><italic toggle="yes">Diabetes</italic></source><year>2013</year><volume>62</volume><issue>10</issue><fpage>3570</fpage><lpage>3581</lpage><pub-id pub-id-type="doi">10.2337/db13-0216</pub-id><pub-id pub-id-type="other">2-s2.0-84891528921</pub-id><pub-id pub-id-type="pmid">23835337</pub-id><pub-id pub-id-type="pmcid">PMC3781452</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Flow chart of patient enrollment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JDR2024-9958586.001.jpg"/></fig><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Associations between the Gensini score and HbA1c variability by univariate linear regression analysis. The Gensini score was negatively correlated with HbA1cTIR ((a) <italic toggle="yes">&#946;</italic> = &#8722;0.629; <italic toggle="yes">r</italic> = 0.001) and positively correlated with SD-HbA1c ((b) <italic toggle="yes">&#946;</italic> = 0.271; <italic toggle="yes">r</italic> = 0.001), CV-HbA1c ((c) <italic toggle="yes">&#946;</italic> = 0.176; <italic toggle="yes">r</italic> = 0.031), HbA1c ((e) <italic toggle="yes">&#946;</italic> = 0.29; <italic toggle="yes">r</italic> &lt; 0.001), and duration ((f) <italic toggle="yes">&#946;</italic> = 0.248; <italic toggle="yes">r</italic> = 0.02). (d) The Gensini score was not correlated with HbA1cVIM.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JDR2024-9958586.002.jpg"/></fig><table-wrap-group position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>(a) Characteristics of participants according to the number of involved vessels. (b) Characteristics of participants according to the tertile of the Gensini score.</p></caption><table-wrap position="anchor" id="tab1a" orientation="portrait"><label>(a)</label><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<bold>1-vessel disease (<italic toggle="yes">n</italic>&#8201;=&#8201;42)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>2-vessel disease (<italic toggle="yes">n</italic>&#8201;=&#8201;56)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>3-vessel disease (<italic toggle="yes">n</italic>&#8201;=&#8201;49)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>r</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (y)</td><td align="center" rowspan="1" colspan="1">62.07 &#177; 8.86</td><td align="center" rowspan="1" colspan="1">63.80 &#177; 9.95</td><td align="center" rowspan="1" colspan="1">66.49 &#177; 12.22</td><td align="center" rowspan="1" colspan="1">0.097</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, male (%)</td><td align="center" rowspan="1" colspan="1">23 (54.8%)</td><td align="center" rowspan="1" colspan="1">35 (62.5%)</td><td align="center" rowspan="1" colspan="1">30 (61.22%)</td><td align="center" rowspan="1" colspan="1">0.567</td></tr><tr><td align="left" rowspan="1" colspan="1">The number of HbA1c measurements</td><td align="center" rowspan="1" colspan="1">5.4 &#177; 0.14</td><td align="center" rowspan="1" colspan="1">5.4 &#177; 0.12</td><td align="center" rowspan="1" colspan="1">5.43 &#177; 0.13</td><td align="center" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking habits (%)</td><td align="center" rowspan="1" colspan="1">12 (28.6%)</td><td align="center" rowspan="1" colspan="1">29 (51.79%)</td><td align="center" rowspan="1" colspan="1">20 (40.82%)</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration (y)</td><td align="center" rowspan="1" colspan="1">5 (9. 12)</td><td align="center" rowspan="1" colspan="1">10 (7, 16)</td><td align="center" rowspan="1" colspan="1">18 (9, 20)<sup><xref rid="fn1" ref-type="table-fn">a</xref></sup><sup>,</sup><sup><xref rid="fn2" ref-type="table-fn">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">134.85 &#177; 13.81</td><td align="center" rowspan="1" colspan="1">134.57 &#177; 18.09</td><td align="center" rowspan="1" colspan="1">138.18 &#177; 24.27</td><td align="center" rowspan="1" colspan="1">0.661</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">80.12 &#177; 10.19</td><td align="center" rowspan="1" colspan="1">76.82 &#177; 10.34</td><td align="center" rowspan="1" colspan="1">76.55 &#177; 11.82</td><td align="center" rowspan="1" colspan="1">0.157</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.01 (1.61, 2.66)</td><td align="center" rowspan="1" colspan="1">2.06 (1.48, 2.77)</td><td align="center" rowspan="1" colspan="1">2.04 (1.5, 2.49)</td><td align="center" rowspan="1" colspan="1">0.894</td></tr><tr><td align="left" rowspan="1" colspan="1">EGFR (mL/min/1.73&#8201;m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">95.83 &#177; 4.49</td><td align="center" rowspan="1" colspan="1">89.58 &#177; 3.89</td><td align="center" rowspan="1" colspan="1">79.98 &#177; 4.08</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.19 &#177; 0.32</td><td align="center" rowspan="1" colspan="1">2.32 &#177; 0.31</td><td align="center" rowspan="1" colspan="1">1.59 &#177; 0.12</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin (%)</td><td align="center" rowspan="1" colspan="1">18 (41.86%)</td><td align="center" rowspan="1" colspan="1">30 (53.57%)</td><td align="center" rowspan="1" colspan="1">37 (75.5%)<sup><xref rid="fn1" ref-type="table-fn">a</xref></sup><sup>,</sup><sup><xref rid="fn2" ref-type="table-fn">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">25.70 (23.83, 27.3)</td><td align="center" rowspan="1" colspan="1">24.52 (23.00, 26.78)</td><td align="center" rowspan="1" colspan="1">24.50 (22.90, 25.95)</td><td align="center" rowspan="1" colspan="1">0.213</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="center" rowspan="1" colspan="1">6.98 (6.52, 7.66)</td><td align="center" rowspan="1" colspan="1">7. 18 (6.66, 8.04)</td><td align="center" rowspan="1" colspan="1">7.88 (7.28, 8.70)<sup><xref rid="fn1" ref-type="table-fn">a</xref></sup><sup>,</sup><sup><xref rid="fn2" ref-type="table-fn">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1cTIR</td><td align="center" rowspan="1" colspan="1">0.7 (0.41, 0.90)</td><td align="center" rowspan="1" colspan="1">0.45 (0.10, 0.67)<sup><xref rid="fn1" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.21 (0, 0.47)<sup><xref rid="fn1" ref-type="table-fn">a</xref></sup><sup>,</sup><sup><xref rid="fn2" ref-type="table-fn">b</xref></sup></td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD-HbA1c</td><td align="center" rowspan="1" colspan="1">0.43 (0.32, 0.71)</td><td align="center" rowspan="1" colspan="1">0.55 (0.34, 0.84)</td><td align="center" rowspan="1" colspan="1">0.65 (0.43, 1)<sup><xref rid="fn1" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1">CV-HbA1c</td><td align="center" rowspan="1" colspan="1">0.07 (0.05, 0.10)</td><td align="center" rowspan="1" colspan="1">0.07 (0.05, 1.00)</td><td align="center" rowspan="1" colspan="1">0.09 (0.06, 0.13)</td><td align="center" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" rowspan="1" colspan="1">VIM-HbA1c</td><td align="center" rowspan="1" colspan="1">0.59 (0.43, 0.953)</td><td align="center" rowspan="1" colspan="1">0.66 (0.47, 0.82)</td><td align="center" rowspan="1" colspan="1">0.72 (0.53, 1.04)</td><td align="center" rowspan="1" colspan="1">0.254</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note:</italic> The continuous variables were expressed as mean standard deviation, and the comparisons were made by analysis of variance. If the data did not conform to the normal distribution, it was expressed as the median (interquartile range) and compared with the nonparametric test. Categorical variables were expressed as frequency (percentage) and compared using a chi-square test. Values are expressed as <italic toggle="yes">n</italic> (%) or median (interquartile range).</p></fn><fn><p>Abbreviations: BMI, body mass index; CV, coefficient of variation; DBP, diastolic blood pressure; EGFR, estimated glomerular filtration; Hb1Ac, glycosylated hemoglobin; HbA1cTIR, HbA1c time in range; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; VIM, variation independent of mean.</p></fn><fn id="fn1"><p>
<sup>a</sup>Statistically significant difference compared to the first group.</p></fn><fn id="fn2"><p>
<sup>b</sup>Statistically significant difference compared to the second group.</p></fn></table-wrap-foot></table-wrap><table-wrap position="anchor" id="tab1b" orientation="portrait"><label>(b)</label><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<bold>T1 (<italic toggle="yes">n</italic>&#8201;=&#8201;50)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>T2 (<italic toggle="yes">n</italic>&#8201;=&#8201;47)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>T3 (<italic toggle="yes">n</italic>&#8201;=&#8201;50)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (y)</td><td align="center" rowspan="1" colspan="1">63.94 &#177; 7.70</td><td align="center" rowspan="1" colspan="1">61.76 &#177; 11.43</td><td align="center" rowspan="1" colspan="1">66.57 &#177; 11.90</td><td align="center" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, male (%)</td><td align="center" rowspan="1" colspan="1">27 (50%)</td><td align="center" rowspan="1" colspan="1">29 (61.7%)</td><td align="center" rowspan="1" colspan="1">31 (62%)</td><td align="center" rowspan="1" colspan="1">0.658</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking habits (%)</td><td align="center" rowspan="1" colspan="1">19 (38%)</td><td align="center" rowspan="1" colspan="1">21 (44.68%)</td><td align="center" rowspan="1" colspan="1">21 (42%)</td><td align="center" rowspan="1" colspan="1">0.798</td></tr><tr><td align="left" rowspan="1" colspan="1">The number of HbA1c measurements</td><td align="center" rowspan="1" colspan="1">5.4 &#177; 0.14</td><td align="center" rowspan="1" colspan="1">5.4 &#177; 0.12</td><td align="center" rowspan="1" colspan="1">5.43 &#177; 0.13</td><td align="center" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration (y)</td><td align="center" rowspan="1" colspan="1">10 (5, 15)</td><td align="center" rowspan="1" colspan="1">10 (6, 20)</td><td align="center" rowspan="1" colspan="1">15 (9, 20)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup><sup>,</sup><sup><xref rid="fn4" ref-type="table-fn">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">134.20 &#177; 14.31</td><td align="center" rowspan="1" colspan="1">133.67 &#177; 18.65</td><td align="center" rowspan="1" colspan="1">140.49 &#177; 24.02</td><td align="center" rowspan="1" colspan="1">0.759</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">78.76 &#177; 9.91</td><td align="center" rowspan="1" colspan="1">77.53 &#177; 11.60</td><td align="center" rowspan="1" colspan="1">77.04 &#177; 11.61</td><td align="center" rowspan="1" colspan="1">0.140</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.78 (1.36, 2. 16)</td><td align="center" rowspan="1" colspan="1">1.97 (1.51, 2.61)</td><td align="center" rowspan="1" colspan="1">2.38 (1.78, 2.78)</td><td align="center" rowspan="1" colspan="1">0.402</td></tr><tr><td align="left" rowspan="1" colspan="1">EGFR (mL/min/1.73&#8201;m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">95.73 &#177; 4.6</td><td align="center" rowspan="1" colspan="1">93.37 &#177; 5.91</td><td align="center" rowspan="1" colspan="1">88.26 &#177; 4.08</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.14 &#177; 0.32</td><td align="center" rowspan="1" colspan="1">2.02 &#177; 0.34</td><td align="center" rowspan="1" colspan="1">2.06 &#177; 0.14</td><td align="center" rowspan="1" colspan="1">0.942</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin (%)</td><td align="center" rowspan="1" colspan="1">21 (42%)</td><td align="center" rowspan="1" colspan="1">27 (57.44%)</td><td align="center" rowspan="1" colspan="1">38 (76%)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">24.6 (23, 26.57)</td><td align="center" rowspan="1" colspan="1">25.7 (23.59, 27.68)</td><td align="center" rowspan="1" colspan="1">24.61 (23.34, 26.12)</td><td align="center" rowspan="1" colspan="1">0.102</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="center" rowspan="1" colspan="1">6.92 (6.42, 7.38)</td><td align="center" rowspan="1" colspan="1">7.62 (6.98, 8.36)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">7.94 (7.19, 8.91)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1cTIR</td><td align="center" rowspan="1" colspan="1">0.75 (0.53, 0.92)</td><td align="center" rowspan="1" colspan="1">0.43 (0.25, 0.66)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.09 (0, 0.3)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup><sup>,</sup><sup><xref rid="fn4" ref-type="table-fn">b</xref></sup></td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD-HbA1c</td><td align="center" rowspan="1" colspan="1">0.44 (0.32, 0.62)</td><td align="center" rowspan="1" colspan="1">0.62 (0.38, 0.88)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.69 (0.42, 1.19)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CV-HbA1c</td><td align="center" rowspan="1" colspan="1">0.07 (0.05, 0.09)</td><td align="center" rowspan="1" colspan="1">0.08 (0.05, 0.10)</td><td align="center" rowspan="1" colspan="1">0.085 (0.06, 0.14)<sup><xref rid="fn3" ref-type="table-fn">a</xref></sup></td><td align="center" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" rowspan="1" colspan="1">VIM-HbA1c</td><td align="center" rowspan="1" colspan="1">0.61 (0.47, 0.86)</td><td align="center" rowspan="1" colspan="1">0.65 (0.45, 0.99)</td><td align="center" rowspan="1" colspan="1">0.74 (0.59, 1.16)</td><td align="center" rowspan="1" colspan="1">0.115</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note:</italic> The centiles of the Gensini score were divided into three groups according to the centile method. Group T1: Gensini score &lt; 20; group T2: Gensini score 20&#8211;50; in group T3, the continuous variables with the Gensini score &gt; 50 were expressed as the mean standard deviation and compared by analysis of variance. If the data did not conform to the normal distribution, it was expressed as the median (interquartile range) and compared with the nonparametric test. Categorical variables were expressed as frequency (percentage) and compared using a chi-square test. Values are expressed as <italic toggle="yes">n</italic> (%) or median (interquartile range).</p></fn><fn><p>Abbreviations: BMI, body mass index; CV, coefficient of variation; DBP, diastolic blood pressure; EGFR, estimated glomerular filtration; Hb1Ac, glycosylated hemoglobin; HbA1cTIR, HbA1c time in range; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; VIM, variation independent of mean.</p></fn><fn id="fn3"><p>
<sup>a</sup>Statistically significant difference compared to the T1 group.</p></fn><fn id="fn4"><p>
<sup>b</sup>Statistically significant difference compared to the T2 group.</p></fn></table-wrap-foot></table-wrap></table-wrap-group><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Relationship between glycosylated hemoglobin variability and the number of coronary artery lesion branches.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th align="center" colspan="2" rowspan="1">
<bold>Model 1</bold>
</th><th align="center" colspan="2" rowspan="1">
<bold>Model 2</bold>
</th><th align="center" colspan="2" rowspan="1">
<bold>Model 3</bold>
</th></tr><tr><th align="center" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>r</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>r</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>OR</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>r</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HbA1cTIR</td><td align="center" rowspan="1" colspan="1">0.09 (0.03, 0.24)</td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" rowspan="1" colspan="1">0.11 (0.04, 0.31)</td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" rowspan="1" colspan="1">0.13 (0.04, 0.41)</td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD-HbA1c</td><td align="center" rowspan="1" colspan="1">2.59 (1.32, 5. 11)</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">2.84 (1.34, 6.05)</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">2.38 (0.98, 5.77)</td><td align="center" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" rowspan="1" colspan="1">CV-HbA1c</td><td align="center" rowspan="1" colspan="1">1.26 (0.96, 1.64)</td><td align="center" rowspan="1" colspan="1">0.093</td><td align="center" rowspan="1" colspan="1">1.32 (0.99, 1.76)</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">1.32 (0.991, 1.76)</td><td align="center" rowspan="1" colspan="1">0.120</td></tr><tr><td align="left" rowspan="1" colspan="1">VIM-HbA1c</td><td align="center" rowspan="1" colspan="1">1.77 (0.84, 3.70)</td><td align="center" rowspan="1" colspan="1">0.142</td><td align="center" rowspan="1" colspan="1">2.39 (1.08, 5.29)</td><td align="center" rowspan="1" colspan="1">0.019</td><td align="center" rowspan="1" colspan="1">2.60 (1.15, 5.90)</td><td align="center" rowspan="1" colspan="1">0.026</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note:</italic> The correlation between the glycosylated hemoglobin variability and the number of coronary artery lesion branches was studied by multivariate logistic regression analysis. In Model 1, no factors were adjusted. In Model 2, sex, age, duration, SBP, DBP, LDL, and use of insulin using were adjusted. Model 3 is adjusted for factors in Model 2 and HbA1c.</p></fn><fn><p>Abbreviations: CV, coefficient of variation; Hb1Ac, glycosylated hemoglobin; HbA1cTIR, HbA1c time in range; OR, odds ratio; SD, standard deviation; VIM, variation independent of mean.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Linear regression analyses for the Gensini score.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th align="center" colspan="2" rowspan="1">
<bold>Unadjusted</bold>
</th><th align="center" colspan="2" rowspan="1">
<bold>Adjusted</bold>
</th></tr><tr><th align="center" rowspan="1" colspan="1">
<bold>&#946;</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>r</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>&#946;</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>r</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HbA1cTIR</td><td align="center" rowspan="1" colspan="1">&#8722;0.629</td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" rowspan="1" colspan="1">&#8722;0.576</td><td align="center" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SD-HbA1c</td><td align="center" rowspan="1" colspan="1">0.271</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.217</td><td align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">CV-HbA1c</td><td align="center" rowspan="1" colspan="1">0.176</td><td align="center" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.160</td><td align="center" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" rowspan="1" colspan="1">VIM-HBA1c</td><td align="center" rowspan="1" colspan="1">0.129</td><td align="center" rowspan="1" colspan="1">0.120</td><td align="center" rowspan="1" colspan="1">0.181</td><td align="center" rowspan="1" colspan="1">0.022</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note:</italic> The adjusted linear logistic regression was adjusted for age, sex, disease duration, systolic blood pressure, diastolic blood pressure, low-density lipoprotein cholesterol, insulin use, and HbA1c.</p></fn><fn><p>Abbreviations: CV, coefficient of variation; HbA1c, glycosylated hemoglobin; HbA1cTIR, HbA1c time in range; SD, standard deviation; VIM, variation independent of mean.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>